Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory BRAF V600 Mutation-Positive Solid Tumors.

Kieran MW, Geoerger B, Dunkel IJ, Broniscer A, Hargrave D, Hingorani P, Aerts I, Bertozzi AI, Cohen KJ, Hummel TR, Shen V, Bouffet E, Pratilas CA, Pearson ADJ, Tseng L, Nebot N, Green S, Russo MW, Whitlock JA.

Clin Cancer Res. 2019 Sep 10. doi: 10.1158/1078-0432.CCR-17-3572. [Epub ahead of print]

PMID:
31506385
2.

BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors.

Schreck KC, Grossman SA, Pratilas CA.

Cancers (Basel). 2019 Aug 28;11(9). pii: E1262. doi: 10.3390/cancers11091262. Review.

3.

Telomere alterations in neurofibromatosis type 1-associated solid tumors.

Rodriguez FJ, Graham MK, Brosnan-Cashman JA, Barber JR, Davis C, Vizcaino MA, Palsgrove DN, Giannini C, Pekmezci M, Dahiya S, Gokden M, Noë M, Wood LD, Pratilas CA, Morris CD, Belzberg A, Blakeley J, Heaphy CM.

Acta Neuropathol Commun. 2019 Aug 28;7(1):139. doi: 10.1186/s40478-019-0792-5.

4.

A novel RBMX-TFE3 gene fusion in a highly aggressive pediatric renal perivascular epithelioid cell tumor.

Argani P, Zhang L, Sung YS, White MJ, Miller K, Hopkins M, Small D, Pratilas CA, Swanson D, Dickson B, Antonescu CR.

Genes Chromosomes Cancer. 2019 Aug 13. doi: 10.1002/gcc.22801. [Epub ahead of print]

PMID:
31408245
5.

Metanephric Adenoma-Epithelial Wilms Tumor Overlap Lesions: An Analysis of BRAF Status.

Wobker SE, Matoso A, Pratilas CA, Mangray S, Zheng G, Lin MT, Debeljak M, Epstein JI, Argani P.

Am J Surg Pathol. 2019 Sep;43(9):1157-1169. doi: 10.1097/PAS.0000000000001240.

PMID:
31192863
6.

Rare BRAF mutations in pancreatic neuroendocrine tumors may predict response to RAF and MEK inhibition.

Allen A, Qin ACR, Raj N, Wang J, Uddin S, Yao Z, Tang L, Meyers PA, Taylor BS, Berger MF, Yaeger R, Reidy-Lagunes D, Pratilas CA.

PLoS One. 2019 Jun 3;14(6):e0217399. doi: 10.1371/journal.pone.0217399. eCollection 2019.

7.

Author Correction: The Rho GTPase Rnd1 suppresses mammary tumorigenesis and EMT by restraining Ras-MAPK signalling.

Okada T, Sinha S, Esposito I, Schiavon G, López-Lago MA, Su W, Pratilas CA, Abele C, Hernandez JM, Ohara M, Okada M, Viale A, Heguy A, Socci ND, Sapino A, Seshan VE, Long S, Inghirami G, Rosen N, Giancotti FG.

Nat Cell Biol. 2019 Apr;21(4):534. doi: 10.1038/s41556-019-0288-3.

PMID:
30842593
8.

Sporadic Malignant Glomus Tumor of the Brachial Plexus With Response to Targeted Therapy Directed Against Oncogenic BRAF.

Cuviello A, Goyal A, Zick A, Ahlawat S, Rodriguez FJ, Belzberg AJ, Pratilas CA.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00261. Epub 2018 May 4. No abstract available.

9.

Eosinophilic Solid and Cystic (ESC) Renal Cell Carcinomas Harbor TSC Mutations: Molecular Analysis Supports an Expanding Clinicopathologic Spectrum.

Palsgrove DN, Li Y, Pratilas CA, Lin MT, Pallavajjalla A, Gocke C, De Marzo AM, Matoso A, Netto GJ, Epstein JI, Argani P.

Am J Surg Pathol. 2018 Sep;42(9):1166-1181. doi: 10.1097/PAS.0000000000001111.

10.

A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.

Wang J, Yao Z, Jonsson P, Allen AN, Qin ACR, Uddin S, Dunkel IJ, Petriccione M, Manova K, Haque S, Rosenblum MK, Pisapia DJ, Rosen N, Taylor BS, Pratilas CA.

Cancer Discov. 2018 Sep;8(9):1130-1141. doi: 10.1158/2159-8290.CD-17-1263. Epub 2018 Jun 7.

11.

Size-based detection of sarcoma circulating tumor cells and cell clusters.

Hayashi M, Zhu P, McCarty G, Meyer CF, Pratilas CA, Levin A, Morris CD, Albert CM, Jackson KW, Tang CM, Loeb DM.

Oncotarget. 2017 Aug 24;8(45):78965-78977. doi: 10.18632/oncotarget.20697. eCollection 2017 Oct 3.

12.

Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase-Driven Leukemias and Other Malignancies.

Bruner JK, Ma HS, Li L, Qin ACR, Rudek MA, Jones RJ, Levis MJ, Pratz KW, Pratilas CA, Small D.

Cancer Res. 2017 Oct 15;77(20):5554-5563. doi: 10.1158/0008-5472.CAN-16-2593. Epub 2017 Sep 18.

13.

The promise of signal transduction in genetically driven sarcomas of the nerve.

Kim A, Pratilas CA.

Exp Neurol. 2018 Jan;299(Pt B):317-325. doi: 10.1016/j.expneurol.2017.08.014. Epub 2017 Aug 30. Review.

PMID:
28859862
14.

Targeted therapy for soft tissue sarcomas in adolescents and young adults.

Steppan DA, Pratilas CA, Loeb DM.

Adolesc Health Med Ther. 2017 Mar 30;8:41-55. doi: 10.2147/AHMT.S70377. eCollection 2017. Review.

15.

Personalized Medicine in the Oncology Clinic: Implementation and Outcomes of the Johns Hopkins Molecular Tumor Board.

Dalton WB, Forde PM, Kang H, Connolly RM, Stearns V, Gocke CD, Eshleman JR, Axilbund J, Petry D, Geoghegan C, Wolff AC, Loeb DM, Pratilas CA, Meyer CF, Christenson ES, Slater SA, Ensminger J, Parsons HA, Park BH, Lauring J.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.16.00046. Epub 2017 May 31.

16.

Perturbation biology nominates upstream-downstream drug combinations in RAF inhibitor resistant melanoma cells.

Korkut A, Wang W, Demir E, Aksoy BA, Jing X, Molinelli EJ, Babur Ö, Bemis DL, Onur Sumer S, Solit DB, Pratilas CA, Sander C.

Elife. 2015 Aug 18;4. doi: 10.7554/eLife.04640.

17.

Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer.

Tricker EM, Xu C, Uddin S, Capelletti M, Ercan D, Ogino A, Pratilas CA, Rosen N, Gray NS, Wong KK, Jänne PA.

Cancer Discov. 2015 Sep;5(9):960-971. doi: 10.1158/2159-8290.CD-15-0063. Epub 2015 Jun 2.

18.

Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: a pooled analysis.

Belum VR, Washington C, Pratilas CA, Sibaud V, Boralevi F, Lacouture ME.

Pediatr Blood Cancer. 2015 May;62(5):798-806. doi: 10.1002/pbc.25429. Epub 2015 Feb 12.

19.

Ifosfamide dose-intensification for patients with metastatic Ewing sarcoma.

Magnan H, Goodbody CM, Riedel E, Pratilas CA, Wexler LH, Chou AJ.

Pediatr Blood Cancer. 2015 Apr;62(4):594-7. doi: 10.1002/pbc.25373. Epub 2015 Jan 28.

20.

The Rho GTPase Rnd1 suppresses mammary tumorigenesis and EMT by restraining Ras-MAPK signalling.

Okada T, Sinha S, Esposito I, Schiavon G, López-Lago MA, Su W, Pratilas CA, Abele C, Hernandez JM, Ohara M, Okada M, Viale A, Heguy A, Socci ND, Sapino A, Seshan VE, Long S, Inghirami G, Rosen N, Giancotti FG.

Nat Cell Biol. 2015 Jan;17(1):81-94. doi: 10.1038/ncb3082. Epub 2014 Dec 22. Erratum in: Nat Cell Biol. 2019 Apr;21(4):534.

21.

Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.

Nissan MH, Pratilas CA, Jones AM, Ramirez R, Won H, Liu C, Tiwari S, Kong L, Hanrahan AJ, Yao Z, Merghoub T, Ribas A, Chapman PB, Yaeger R, Taylor BS, Schultz N, Berger MF, Rosen N, Solit DB.

Cancer Res. 2014 Apr 15;74(8):2340-50. doi: 10.1158/0008-5472.CAN-13-2625. Epub 2014 Feb 27.

22.

Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor.

Callahan MK, Masters G, Pratilas CA, Ariyan C, Katz J, Kitano S, Russell V, Gordon RA, Vyas S, Yuan J, Gupta A, Wigginton JM, Rosen N, Merghoub T, Jure-Kunkel M, Wolchok JD.

Cancer Immunol Res. 2014 Jan;2(1):70-9. doi: 10.1158/2326-6066.CIR-13-0160.

23.

Perturbation biology: inferring signaling networks in cellular systems.

Molinelli EJ, Korkut A, Wang W, Miller ML, Gauthier NP, Jing X, Kaushik P, He Q, Mills G, Solit DB, Pratilas CA, Weigt M, Braunstein A, Pagnani A, Zecchina R, Sander C.

PLoS Comput Biol. 2013;9(12):e1003290. doi: 10.1371/journal.pcbi.1003290. Epub 2013 Dec 19.

24.

Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas.

Lito P, Pratilas CA, Joseph EW, Tadi M, Halilovic E, Zubrowski M, Huang A, Wong WL, Callahan MK, Merghoub T, Wolchok JD, de Stanchina E, Chandarlapaty S, Poulikakos PI, Fagin JA, Rosen N.

Cancer Cell. 2012 Nov 13;22(5):668-82. doi: 10.1016/j.ccr.2012.10.009.

25.

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

Ercan D, Xu C, Yanagita M, Monast CS, Pratilas CA, Montero J, Butaney M, Shimamura T, Sholl L, Ivanova EV, Tadi M, Rogers A, Repellin C, Capelletti M, Maertens O, Goetz EM, Letai A, Garraway LA, Lazzara MJ, Rosen N, Gray NS, Wong KK, Jänne PA.

Cancer Discov. 2012 Oct;2(10):934-47. doi: 10.1158/2159-8290.CD-12-0103. Epub 2012 Sep 7.

26.

Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.

Ambrosini G, Pratilas CA, Qin LX, Tadi M, Surriga O, Carvajal RD, Schwartz GK.

Clin Cancer Res. 2012 Jul 1;18(13):3552-61. doi: 10.1158/1078-0432.CCR-11-3086. Epub 2012 May 1.

27.

Targeting oncogenic BRAF in human cancer.

Pratilas CA, Xing F, Solit DB.

Curr Top Microbiol Immunol. 2012;355:83-98. doi: 10.1007/82_2011_162.

28.

Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF.

Xing F, Persaud Y, Pratilas CA, Taylor BS, Janakiraman M, She QB, Gallardo H, Liu C, Merghoub T, Hefter B, Dolgalev I, Viale A, Heguy A, De Stanchina E, Cobrinik D, Bollag G, Wolchok J, Houghton A, Solit DB.

Oncogene. 2012 Jan 26;31(4):446-57. doi: 10.1038/onc.2011.250. Epub 2011 Jul 4.

29.

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.

Joseph EW, Pratilas CA, Poulikakos PI, Tadi M, Wang W, Taylor BS, Halilovic E, Persaud Y, Xing F, Viale A, Tsai J, Chapman PB, Bollag G, Solit DB, Rosen N.

Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14903-8. doi: 10.1073/pnas.1008990107. Epub 2010 Jul 28.

30.

Genomic and biological characterization of exon 4 KRAS mutations in human cancer.

Janakiraman M, Vakiani E, Zeng Z, Pratilas CA, Taylor BS, Chitale D, Halilovic E, Wilson M, Huberman K, Ricarte Filho JC, Persaud Y, Levine DA, Fagin JA, Jhanwar SC, Mariadason JM, Lash A, Ladanyi M, Saltz LB, Heguy A, Paty PB, Solit DB.

Cancer Res. 2010 Jul 15;70(14):5901-11. doi: 10.1158/0008-5472.CAN-10-0192. Epub 2010 Jun 22.

31.

Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response.

Pratilas CA, Solit DB.

Clin Cancer Res. 2010 Jul 1;16(13):3329-34. doi: 10.1158/1078-0432.CCR-09-3064. Epub 2010 May 14. Review.

32.

Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244).

Dry JR, Pavey S, Pratilas CA, Harbron C, Runswick S, Hodgson D, Chresta C, McCormack R, Byrne N, Cockerill M, Graham A, Beran G, Cassidy A, Haggerty C, Brown H, Ellison G, Dering J, Taylor BS, Stark M, Bonazzi V, Ravishankar S, Packer L, Xing F, Solit DB, Finn RS, Rosen N, Hayward NK, French T, Smith PD.

Cancer Res. 2010 Mar 15;70(6):2264-73. doi: 10.1158/0008-5472.CAN-09-1577. Epub 2010 Mar 9.

33.

(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway.

Pratilas CA, Taylor BS, Ye Q, Viale A, Sander C, Solit DB, Rosen N.

Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4519-24. doi: 10.1073/pnas.0900780106. Epub 2009 Feb 27.

34.

Genetic predictors of MEK dependence in non-small cell lung cancer.

Pratilas CA, Hanrahan AJ, Halilovic E, Persaud Y, Soh J, Chitale D, Shigematsu H, Yamamoto H, Sawai A, Janakiraman M, Taylor BS, Pao W, Toyooka S, Ladanyi M, Gazdar A, Rosen N, Solit DB.

Cancer Res. 2008 Nov 15;68(22):9375-83. doi: 10.1158/0008-5472.CAN-08-2223.

35.

Therapeutic strategies for targeting BRAF in human cancer.

Pratilas CA, Solit DB.

Rev Recent Clin Trials. 2007 May;2(2):121-34. Review.

PMID:
18473997
36.

BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.

Leboeuf R, Baumgartner JE, Benezra M, Malaguarnera R, Solit D, Pratilas CA, Rosen N, Knauf JA, Fagin JA.

J Clin Endocrinol Metab. 2008 Jun;93(6):2194-201. doi: 10.1210/jc.2007-2825. Epub 2008 Apr 1.

37.

3'-deoxy-3'-[18F]fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF-dependent tumors to MEK inhibition.

Solit DB, Santos E, Pratilas CA, Lobo J, Moroz M, Cai S, Blasberg R, Sebolt-Leopold J, Larson S, Rosen N.

Cancer Res. 2007 Dec 1;67(23):11463-9.

38.

BRAF mutation predicts sensitivity to MEK inhibition.

Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR, Rosen N.

Nature. 2006 Jan 19;439(7074):358-62. Epub 2005 Nov 6.

39.

Supplemental Content

Loading ...
Support Center